Literature DB >> 19955112

The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study.

Nicola Z Hobbs1, Susie M D Henley, Gerard R Ridgway, Edward J Wild, Roger A Barker, Rachael I Scahill, Josephine Barnes, Nick C Fox, Sarah J Tabrizi.   

Abstract

BACKGROUND: Unbiased longitudinal studies are needed to understand the distributed neurodegenerative changes of Huntington's disease (HD). They may also provide tools for assessing disease-modifying interventions. The authors investigated the progression of regional atrophy in premanifest and early HD compared with controls.
METHODS: Nine controls, 17 premanifest and 21 early HD subjects underwent volumetric MRI at baseline and 2 years. Premanifest subjects were on average 18.1 years before predicted motor onset. Non-linear registration was used to model within-subject change over the scanning interval, and statistical parametric mapping was used to examine group differences and associations with clinical variables.
RESULTS: In early HD, increased grey-matter (GM) atrophy rates were evident throughout the subcortical GM and over selective cortical regions compared with controls. This group also demonstrated strikingly widespread increases in white-matter (WM) atrophy rates. The authors observed no significant differences between premanifest HD and controls. Longer CAG was associated with higher atrophy rates over large WM areas including brainstem and internal capsule and over small GM regions including thalamus and occipital cortex. Worse baseline motor score was associated with regionally increased rates in the thalamus, internal capsule and occipital lobe. Sample-size calculations indicate that 19 and 24 early HD subjects per treatment arm would need to complete a 2-year trial in order to detect a 50% reduction in WM and GM atrophy rates respectively.
CONCLUSIONS: Degeneration of structural connectivity may play an important role in early HD symptoms. Assessment of WM and GM changes will be important in understanding the complexity of HD and its treatment.

Entities:  

Mesh:

Year:  2009        PMID: 19955112     DOI: 10.1136/jnnp.2009.190702

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  45 in total

1.  Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation.

Authors:  D S Adnan Majid; Adam R Aron; Wesley Thompson; Sarah Sheldon; Samar Hamza; Diederick Stoffers; Dominic Holland; Jody Goldstein; Jody Corey-Bloom; Anders M Dale
Journal:  Mov Disord       Date:  2011-09-19       Impact factor: 10.338

2.  Complex relationships between cerebral blood flow and brain atrophy in early Huntington's disease.

Authors:  J Jean Chen; David H Salat; H Diana Rosas
Journal:  Neuroimage       Date:  2011-09-16       Impact factor: 6.556

3.  Longitudinal behavioral, cross-sectional transcriptional and histopathological characterization of a knock-in mouse model of Huntington's disease with 140 CAG repeats.

Authors:  Aaron C Rising; Jia Xu; Aaron Carlson; Vincent V Napoli; Eileen M Denovan-Wright; Ronald J Mandel
Journal:  Exp Neurol       Date:  2010-12-28       Impact factor: 5.330

Review 4.  Progress and prospects for genetic modification of nonhuman primate models in biomedical research.

Authors:  Anthony W S Chan
Journal:  ILAR J       Date:  2013

5.  Magnetic resonance perfusion imaging of resting-state cerebral blood flow in preclinical Huntington's disease.

Authors:  Robert C Wolf; Georg Grön; Fabio Sambataro; Nenad Vasic; Nadine D Wolf; Philipp A Thomann; Carsten Saft; G Bernhard Landwehrmeyer; Michael Orth
Journal:  J Cereb Blood Flow Metab       Date:  2011-05-11       Impact factor: 6.200

6.  Maximizing power to track Alzheimer's disease and MCI progression by LDA-based weighting of longitudinal ventricular surface features.

Authors:  Boris A Gutman; Xue Hua; Priya Rajagopalan; Yi-Yu Chou; Yalin Wang; Igor Yanovsky; Arthur W Toga; Clifford R Jack; Michael W Weiner; Paul M Thompson
Journal:  Neuroimage       Date:  2013-01-04       Impact factor: 6.556

7.  Empowering imaging biomarkers of Alzheimer's disease.

Authors:  Boris A Gutman; Yalin Wang; Igor Yanovsky; Xue Hua; Arthur W Toga; Clifford R Jack; Michael W Weiner; Paul M Thompson
Journal:  Neurobiol Aging       Date:  2014-08-27       Impact factor: 4.673

8.  Monitoring Huntington's disease progression through preclinical and early stages.

Authors:  Chris Tang; Andrew Feigin
Journal:  Neurodegener Dis Manag       Date:  2012-08-01

Review 9.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

10.  Unbiased tensor-based morphometry: improved robustness and sample size estimates for Alzheimer's disease clinical trials.

Authors:  Xue Hua; Derrek P Hibar; Christopher R K Ching; Christina P Boyle; Priya Rajagopalan; Boris A Gutman; Alex D Leow; Arthur W Toga; Clifford R Jack; Danielle Harvey; Michael W Weiner; Paul M Thompson
Journal:  Neuroimage       Date:  2012-11-12       Impact factor: 6.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.